AR and neoplasm: Thereafter, they established ZR–75–1 xenografts in mice and found that the AR antagonist enzalutamide could only inhibit estradiol (E2)–stimulated tumor proliferation in the short term, whereas the AR agonist dihydrotestosterone (DHT) and the selective androgen receptor modulators (SARM) enobosarm resulted in lasting inhibition of tumor growth, even for over 90 days.